Increased Advisory Cmte. Preparation Ahead May Challenge FDA, Sponsors

The potential upturn in the number of advisory committees convened by FDA could translate into a significant increase in the behind-the-scenes meeting preparation workload for both industry and the agency

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet